← Back to ICCM filing summaryOriginal filing text · Part I
Item 11 — Quantitative and Qualitative Disclosures About Market Risk
Icecure Medical Ltd. · 20-F · FY 2025 · Period ended Dec 31, 2025
View complete filing on SEC EDGAR ↗This is the extracted source text from the SEC filing. Formatting may differ from the original document.
ABOUT MARKET RISK
In the ordinary course of
our operations, we are exposed to certain market risks, primarily changes in foreign currency exchange rates and interest rates.
Quantitative and Qualitative Disclosure About
Market Risk
We are exposed to market
risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse
changes in financial market prices and rates. Our current investment policy is to invest available cash in bank deposits with banks that
have a credit rating of at least A-minus. Currently, a substantial majority of our cash is held in our operating cash bank account. Given
the current low rates of interest we receive, we will not be adversely affected if such rates are reduced. Our market risk exposure is
primarily a result of NIS/U.S. dollar exchange rates, which is discussed in the following paragraph.
133
Foreign Currency Exchange Risk
Our functional and reporting
currency is the U.S. dollar. Although the U.S. dollar is our functional currency, a significant portion of our expenses are denominated
in NIS and a relatively small portion of our expenses is denominated in Euros, and currently most of our revenues are denominated in
U.S. dollars. Therefore, our foreign currency exposures give rise to market risk associated with exchange rate movements of the U.S.
dollar, mainly against the NIS and the Euro. Our NIS and Euro expenses consist principally of payroll to our employees in Israel, payments
made to subcontractors for purchasing components to our products, research and development activities and marketing and sales activities.
We anticipate that a significant portion of our expenses will continue to be denominated in currencies other than the U.S. dollar. If
the U.S. dollar fluctuates significantly against either the NIS or the Euro, it may have a negative impact on our results of operations.
Due to the fact that exchange
rates between the U.S. dollar and the NIS (as well as between the U.S. dollar and other currencies) fluctuate continuously, such fluctuations
have an impact on our results and period-to-period comparisons of our results. The effects of foreign currency remeasurements are reported
in our consolidated statements of operations. In order to reduce some of this currency exposure, we keep cash balances in NIS. These
measures, however, may not adequately protect us from the material adverse effects of such fluctuations.
As of December 31, 2025,
we did not enter into any hedging transactions, but we may do so in the future. Even if we do enter into such hedge transactions in the
future, we cannot guarantee that such measures will effectively protect us from adverse effects due to the impact of fluctuations in
currency exchange rates.
In addition, we have balance
sheet exposure arising from assets and liabilities denominated in currencies other than the U.S. dollar, mainly in NIS and Euros. Any
change of the conversion rates between the U.S. dollar and these currencies may create financial gain or loss.
The tables below provide
information as of the dates indicated regarding our foreign currency-denominated monetary assets and liabilities as of December 31, 2025
(U.S. dollars in thousands).
Assets:
NIS $ 579
EUR 294
Other currencies 99
Total 972
Liabilities:
NIS 3,481
EUR -
Other currencies 31
Total 3,512
Net Liabilities 2,540